Abstract. MicroRNA (miR)-146a levels are reduced in peripheral blood mononuclear cells of patients with systemic lupus erythematosus (SLE); however, its function is not well understood. The present study investigated the role of miR-146a in the regulation of lipopolysaccharide (LPS)-induced inflammation in THP-1 cells. A miR-146a mimic and an inhibitor were used to overexpress and downregulate miR-146a expression, respectively. Reverse transcription-quantitative PCR and western blot analyses were performed to evaluate interleukin (IL)-1 receptor-associated kinase 1 (IRAK1) expression, and western blot analysis was applied to assess nuclear factor-κB activation by analyzing p65 subunit levels in the nucleus. To investigate the effects of miR-146a on LPS-induced inflammation, IL-6 and tumor necrosis factor-α (TNF-α) levels were also measured using ELISA. The results of the present study revealed that miR-146a overexpression significantly reduced IRAK1 expression, reduced p65 levels in the nucleus and reduced IL-6 and TNF-α levels in the supernatant of the cell culture medium of THP-1 cells following LPS treatment. Luciferase assays confirmed IRAK1 to be a direct target of miR-146a in THP-1 cells. In conclusion, miR-146a may regulate IRAK1 expression and inhibit the activation of inflammatory signals and secretion of pro-inflammatory cytokines. The present study revealed, at least in part, the mechanisms by which miR-146a regulate the inflammatory response in SLE.

Introduction

MicroRNAs (miRNAs/miRs) are endogenous non-coding RNA molecules, 19-25 nucleotides in length, that exert post-transcriptional inhibitory effects on gene expression (1). To date, abnormal miRNA expression has been observed in a number of diseases, including cancer, systemic lupus erythematosus (SLE), autoimmune diabetes, atherosclerosis and rheumatoid arthritis (RA) (2-4). In particular, miR-146 is a miRNA that serves an important role in the regulation of the immune response by targeting genes to mediate downstream pathophysiological processes, with the interleukin (IL)-1 receptor-associated kinase 1 (IRAK1)/tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) TRAF6/NF-κB axis as the most important target (5). It has been reported that miR-146a inhibits the activation of donor T cells in acute graft-vs.-host disease by targeting TRAF6, leading to reduced TNF transcription (6). Human miR-146 exists in two forms, miR-146a and miR-146b, the former of which has a seed sequence of 5' -UGA GAA CUG AAU UCC AUG GGU U-3' and is highly expressed in macrophages, mononuclear cells and T lymphocytes (7).

SLE is a complex chronic autoimmune inflammatory disease that is caused by inflammatory responses mediated by the lack of self-tolerance in the immune system. Innate and adaptive immune responses appear to be involved in the development of SLE. A variety of immune cell types, including monocytes, lymphocytes, mediated by a number of cytokines, including type I interferon (IFN) and IL-6, have been previously reported to serve their roles in this process (8). Indeed, previous studies have demonstrated that miR-146a expression is reduced in the peripheral blood mononuclear cells (PBMCs) of patients with SLE (9,10). A pilot study performed by Zhou et al. (unpublished data) revealed that miR-146a levels were lower in the serum of patients with SLE. These findings suggested that miR-146a may be associated with the development and progression of SLE.

A previous study revealed that interleukin (IL)-1 receptor-associated kinase 1 (IRAK1) is a potential target of...
miR-146a (11). IRAK1 is the critical molecule in the Toll-like receptor (TLR)-4-myeloid differentiation primary response 88 (MyD88) signaling pathway. IRAK1 is phosphorylated after combining with MyD88, and forms a complex with TRAF6. This complex then activates inhibitor of nuclear factor (NF)-κB kinase (IKKβ) and induces the activation and translocation of the NF-κB transcription factor into the nucleus. Activated NF-κB subsequently induces the synthesis and secretion of large quantities of inflammatory cytokines (12).

Immunosuppressive therapy is commonly applied during the clinical management of patients with SLE. Under these conditions, patients are predisposed to infection, including nosocomial and latent infections, which in turn may exacerbate SLE symptoms (13). Pathogen-associated molecular patterns such as lipopolysaccharide (LPS) are the most common etiological agents that induce inflammatory responses by activating the TLR/IRAK1/NF-κB signaling pathway (14). Therefore, the aim of the present study was to investigate the regulatory effects of miR-146a on inflammatory responses by analyzing its effects on the expression of IRAK1 and downstream NF-κB activation. In addition, the current study aimed to investigate the possible infection-associated mechanisms of miR-146a in the pathogenesis of SLE.

Materials and methods

Cell culture and transfection. The human acute monocytic leukemia THP-1 cell line was purchased from the Cell Bank of the Chinese Academy of Sciences. THP-1 cells were cultured using RPMI-1640 culture medium supplemented with 10% fetal bovine serum (both Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 mg/ml streptomycin at 37°C and 5% CO₂. Cells in the logarithmic growth phase were seeded into 6-well plate (1x10⁶ cells/well) and incubated overnight. They were subsequently transfected with 50 nM miR-146a mimic (cat. no. miR 10000449), 50 nM negative control (NC; cat. no. miR 01101) mimic, 100 nM miR-146a inhibitor or (cat. no. miR 20000449) 100 nM inhibitor NC (cat. no. miR 02101). All from Guangzhou RiboBio Co., Ltd.) using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) before the culture medium was replaced with fresh balanced salt solution (Beijing Solarbio Science & Technology Co., Ltd.) using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 mg/ml streptomycin at 37°C and 5% CO₂. Cells in the logarithmic growth phase were seeded into 6-well plate (1x10⁶ cells/well) and incubated overnight. They were subsequently transfected with 50 nM miR-146a mimic (cat. no. miR 10000449), 50 nM negative control (NC; cat. no. miR 01101) mimic, 100 nM miR-146a inhibitor or (cat. no. miR 20000449) 100 nM inhibitor NC (cat. no. miR 02101). All from Guangzhou RiboBio Co., Ltd.) using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. For the blank control, corresponding quantities of Opti-MEM (Gibco; Thermo Fisher Scientific, Inc.) solution were used in place of RNA during transfection (15).

Stimulation of cells with LPS and cell grouping. At 24 h following transfection, THP-1 cells were washed with Hank's balanced salt solution (Beijing Solarbio Science & Technology Co., Ltd.) before the culture medium was replaced with fresh RPMI-1640 medium. A final concentration of 1 µg/ml LPS (Sigma-Aldrich; Merck KGaA) was subsequently added into the culture medium, followed by incubation for a further 3 h. The cells were then collected for the measurement of IRAK1 and p68 expression, whilst the supernatant of the culture medium was collected for the measurement of cytokine levels, as described previously (15). The cells were divided into the following experimental groups: Blank control, no RNA transfection or LPS treatment; LPS group, treated with LPS only; mimic group, miR-146 amimic+LPS; NC mimic group, NC mimic + LPS; inhibitor group, miR-146a inhibitor + LPS; and inhibitor NC group, inhibitor NC + LPS.

Reverse transcription-quantitative PCR (RT-qPCR). For the measurement of miRNA expression, small RNA was extracted from cells using the mirVana PARIS kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). cDNA was then reverse transcribed from small RNA using the TaqMan® MicroRNA RT kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to manufacturer's protocol. The thermocycling conditions were as follows: 16°C for 30 min, 42°C for 30 min, 85°C for 5 min and 4°C hold. miR-146a expression levels were measured using TaqMan® MicroRNA Assay kit (Assay ID, 000468; Applied Biosystems; Thermo Fisher Scientific, Inc.), the primers, which are patented, were provided by the manufacturer as part of the kit. U6 expression were used for the normalization of miRNA expression.

To determine mRNA expression levels, total RNA was extracted from cells using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.), and then reverse transcription was performed using High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to manufacturer's protocol. The thermocycling conditions used was as follows: 25°C for 10 min, 37°C for 120 min, 85°C for 5 min and 4°C hold. qPCR was performed to measure IRAK1 mRNA levels in cells using PowerUp™ SYBR™ Green Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc.). GAPDH was used as an internal reference. The sequences of the primers used were as follows: IRAK1 forward, 5'-GTGCTTAGACCTTGGTCTG-3' and reverse, 5'-TGTTGCCTGGGGTCTTC-3'; and GAPDH forward, 5'-CCATGTTCGTACGGTGTT-3' and reverse, 5'-TGAGTCTCTCCAGATACC-3'.

Both qPCR assays aforementioned were performed using ABI Real Time PCR System 7500 (Applied Biosystems; Thermo Fisher Scientific, Inc.) using the following thermocycling protocol: Initiation reaction at 50°C for 2 min and 10 min at 95°C, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. The relative expression levels of miR-146a and IRAK1 were determined using the 2⁻ΔΔCT method (16).

Western blotting. Following treatment with LPS for 3 h, the cells were collected and total protein was extracted using RIPA buffer (Pierce; Thermo Fisher Scientific, Inc.) supplemented with a cocktail of protease and phosphatase inhibitors (Sigma-Aldrich; Merck KGaA). Proteins from the nuclear fraction were extracted using a Nuclear Protein Extraction Kit (cat. R0050; Beijing Solarbio Science & Technology Co., Ltd.), according to the manufacturer's protocols. Protein concentrations were determined using a bicinchoninic acid assay protein quantification kit (Pierce; Thermo Fisher Scientific, Inc.). cDNA was then extracted from cells using the mirVana PARIS kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to manufacturer's protocol. The protein samples were then heat-denatured, and 5 µg protein/lane was separated on a 10% SDS-PAGE gel, prior to transferral to polyvinylidene difluoride membranes. The membranes were subsequently blocked in 5% bovine serum albumin (Sigma-Aldrich; Merck KGaA), which was prepared in a TBS-T buffer (50 mM Tris, pH 8.0, and 150 mM NaCl, containing 0.05% Tween-20) and incubated overnight at 4°C. Subsequently, the membranes were incubated with primary antibodies against anti-IRAK1 (cat. no. SC-5288; dilution,
Statistical analysis. The data are presented as the mean ± standard deviation. One-way analysis of variance followed by the least significance difference post hoc test was performed to determine statistical significance among different groups using the SPSS software package (version 16.0; SPSS Inc.). P<0.05 was considered to indicate a statistically significant difference.

Results

miR-146a regulates IRAK1 expression in THP-1 cells. miR-146a mimics miR-146a inhibitor were first transfected into THP-1 cells prior to RT-qPCR analysis. Transfection with miR-146a mimic significantly increased miR-146a expression (>400-fold) whilst transfection with miR-146a inhibitor significantly reduced miR-146a expression (by ~70%); with differences observed compared with the blank control or corresponding NC groups (P<0.01; Fig. 1A). IRAK1 mRNA expression was subsequently measured in THP-1 cells transfected with miR-146a mimic or inhibitor. miR-146a overexpression using the miR-146a mimic led to a significant reduction in IRAK1 mRNA expression (by ~88% relative to blank control; P<0.01 vs. mimic NC), whereas transfection with the miR-146a inhibitor led to a significant increase in IRAK1 expression (by ~20% relative to blank control; P<0.01 vs. inhibitor NC; Fig. 1B). At the protein level, cells transfected with the miR-146a mimic exhibited a significant reduction in IRAK1 expression compared with the mimic NC, whereas miR-146a inhibitor transfection significantly increased IRAK protein levels (P<0.01 vs. inhibitor NC; Fig. 2A and B). There were no significant differences between the blank control and two corresponding NC groups (P>0.05 blank control vs. mimic NC and P>0.05 blank control vs. inhibitor NC; Fig. 2A and B).

miR-146a modulates NF-κB activation by regulating IRAK1 expression under inflammatory conditions. THP-1 cells were treated with LPS to induce inflammation, which significantly augmented IRAK1 expression when compared with the blank control group (P<0.01; Fig. 3A and B). Under inflammatory conditions, transfection with miR-146a mimic significantly reduced IRAK1 expression, whereas transfection with miR-146a inhibitor significantly increased IRAK1 levels compared with the corresponding NC groups (P<0.01; Fig. 3A and B). As NF-κB is a downstream molecule of IRAK1 (17), western blot analysis was subsequently performed to measure the nuclear protein levels of p65; a subunit of NF-κB. Nuclear p65 levels were significantly higher in the LPS group compared with those in the blank control group (P<0.01; Fig. 3C). The changes in nuclear NF-κB p65 protein levels in cells transfected with either miR-146a mimic or miR-146a inhibitor mirrored those of IRAK1 levels in the corresponding treatment groups (Fig. 3B and C). These results suggested that miR-146a regulates NF-κB activation in the presence of LPS, by modulating the expression of IRAK1.

miR-146a inhibits IL-6 and TNF-α secretion. ELISA results demonstrated significantly increased IL-6 and TNF-α levels in the supernatant of cells in the LPS group when compared with cells in the blank control group (P<0.01; Fig. 4). miR-146a overexpression significantly reduced IL-6 and TNF-α secretion compared with the NC mimic groups (P<0.01). By
contrast, transfection with the miR-146a inhibitor significantly increased IL-6 and TNF-α secretion when compared with the inhibitor NC group (P<0.01; Fig. 4). These findings suggested that LPS stimulation induced inflammatory responses in THP-1 cells by increasing the secretion of inflammatory cytokines; a process that is negatively regulated by miR-146a.

**IRAK1 is a direct target of miR-146a.** To investigate whether miR-146a can interact with the IRAK1 mRNA 3'-UTR, a luciferase reporter assay was performed. Prior to this assay, the predicted targets of this miRNA were revealed using TargetScan (version 7.2). Two evolutionarily conserved potential miR-146a target sites were discovered in the 3'-UTR of IRAK1 mRNA (positions 40-47 and 56-63; Fig. 5A). In the group co-transfected with miR-146a mimics and the wild-type 3'-UTR IRAK1 sequence, luciferase activity was significantly repressed when compared with the blank control group, while no significant difference was observed in cells co-transfected with the NC mimic (P<0.01; Fig. 5B). When the IRAK1 3'-UTR sequence was replaced with a mutant sequence (Fig. 5C), no significant differences were observed in the luciferase activity of cells co-transfected with the miR-146a mimic when compared with the blank control group (Fig. 5D). These results suggested that miR-146a directly targets the IRAK1 3'-UTR.

**Discussion**

SLE is a chronic diffuse connective tissue disease that is caused by inflammatory responses associated with autoimmunity (18). Although the mechanisms underlying SLE pathogenesis are unclear, the current consensus is that SLE may be associated with disturbances in the immune response, predisposing genetic factors, sexual hormone levels and exogenous stimulation (19). Dai et al (19) reported significant differences in the expression profiles of miRNAs between PBMCs derived from patients with SLE and healthy controls. Specifically, seven miRNAs were discovered to be downregulated whilst nine miRNAs were found to be upregulated in patients with SLE. Tang et al (20) discovered that the expression of miR-146a in PBMCs was significantly lower in patients with SLE compared with the control group, further suggesting that miR-146a negatively regulates the IFN-1 signaling pathway. It has been established that type I IFN serves a key role in SLE (20,21). Immune complexes of autoantibodies against self-nucleoproteins and self-DNA from lupus patients are known to induce IFN-α production in plasmacytid dendritic cells (22). Once induced, type I IFN binds
to its receptors to initiate downstream signaling by activation of STAT proteins, ultimately leading to the transcription of target genes (20). Reduced expression of miR-146a in patients with SLE and correlation between miR-146a levels and disease activity have been previously reported (20,23). miR-146a has been demonstrated to inhibit the type I IFN pathway by down-regulating IFN regulatory factor 5 (IRF-5) and STAT-1 (20).

IRAK1, one of the regulatory targets of miR-146a, is a critical signaling molecule involved in the TLR4 signal transduction pathway. When the TLR is activated by pathogens or antigen-antibody complexes, it activates the associated adaptor protein IRAKI by the downstream My D88-dependent signaling pathway, leading to the activation of TRAF6, IκKβ and eventually NF-κB (24,25). The findings of the present study demonstrated that miR-146a overexpression may down-regulate the expression of IRAK1, reduce NF-κB activation and inhibit the secretion of pro-inflammatory cytokines, a signaling cascade that may serve as one of the mechanisms underlying miR-146a-mediated regulation of inflammatory responses in SLE.

Patients with SLE are predisposed to infection due to alterations in the immune system as a result of immunosuppressive therapy. As a result, infections may exacerbate SLE by promoting inflammatory responses. The development and progression of SLE is associated with enhanced inflammatory responses and dysregulated pro-inflammatory cytokines secretion (26). IL-6 and TNF-α expression are generally increased in patients with SLE compared with healthy individuals (27-29). The levels of IL-6 and TNF-α are positively associated with disease progression and serum levels of anti-double-stranded (ds) DNA antibody (29,30). IL-6 is an important type II T helper cell cytokine that is secreted by a variety of cell types, including T cells and monocytes, and stimulates the production of anti-ds DNA autoimmune antibodies in patients with SLE. This subsequently leads to the production of IL-6, and the cycle begins again (30). TNF-α activates a number of inflammatory cells, which infiltrate multiple organs and induce inflammation-associated damage (30-32). The activation of NF-κB promotes the expression of pro-inflammatory cytokines including IL-6 and TNF-α (33). The results of the
present study indicated that miR-146a may inhibit the activation of NF-κB, thereby decreasing the expression of IL-6 and TNF-α. Similarly, Du et al. (34) demonstrated that miR-146a suppresses the β-glucan-induced production of IL-6 and TNF-α by inhibiting the dectin-1/tyrosine-protein kinase SYK/NF-κB signaling pathway. These observations suggest that the downregulation of miR-146a may eliminate its regulatory effects on the secretion of pro-inflammatory cytokines, leading to an increase in IL-6 and TNF-α levels. This may promote the development of SLE, particularly under conditions of infection. Ultimately, miR-146a may regulate IRAK1 expression and inhibit the activation of inflammatory signals, leading to the secretion of pro-inflammatory cytokines that may be involved in SLE pathogenesis.

Although an association between miR-146a and inflammation was observed in vitro in the present study, the clinical significance of miR-146a would need to be addressed in future studies. Previous studies have observed aberrant miR-146a expression in blood cells, including PBMCs, T and B cells (35-37). Procedures involving cell isolation and extraction are complex, and therefore not suitable for clinical detection. Alternatively, it has been clearly demonstrated that miRNA remains stable in the serum and other bodily fluids (38). Therefore, the serum levels of miR-146a in patients with SLE and healthy individuals, and the potential application of serum miRNA as a tool for monitoring SLE in a clinical setting, remain potential avenues for further investigation. The in vitro experiments performed in the present study revealed that miR-146a may regulate the expression of IL-6 and TNF-α in THP-1 cells; therefore, in vivo miR-146a levels may be associated with the levels of IL-6 and TNF-α. A clinical trial is currently in progress involving >120 patients with SLE, in which the patients will be divided into active and inactive groups according to the Systemic Lupus Erythematosus Disease Activity Index. In addition, the role of the miR-146a/IRAK1/NF-κB axis will need to be investigated. Finally, the association between miR-146a and other autoimmune diseases, including RA and Sjogren's syndrome, are also interesting topics of future study.

Acknowledgements
Not applicable.

Funding
This study was supported by the National High Technology Research and Development Program (grant no. 2015AA021107), the Natural Science Foundation of Tianjin (grant nos. 17JCYBJC27500 and 17JCYBJC26200), the National Natural Science Foundation of China (grant no. 81602403) and the Clinical Research Foundation of Tianjin Fist Central Hospital (grant no. CF201812).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
HM and CZ designed the study, analyzed the data, and contributed significantly to the preparation of the manuscript. LZ and KW performed the reverse transcription-quantitative PCR and western blot experiments. QQ and MW performed the cell culture experiments. PS and LY performed the ELISA experiments.

Ethics approval and consent to participate
Not applicable.
IFN priming is necessary but not sufficient to Effect of hydroxychloroquine treatment MicroRNA -146A contrib

References

1. Ranganathan K and Sivasankar V: MicroRNAs-biology and clinical applications. J Oral Maxillofac Pathol 18: 229-234, 2014.
2. Pilecki V, Ciojoneanu-Petric R, Maralani M, Neagoe IB and Sandulescu R: MicroRNAs as regulators of apoptosis mechanisms in cancer. Clij Med 89: 50-55, 2016.
3. Miao CG, Yang YY, He X, Huang C, Huang Y, Zhang L, Lv XW, Jin Y and Li J: The emerging role of microRNAs in the pathogenesis of systemic lupus erythematosus. Cell Signal 25: 1828-1836, 2013.
4. Sharma AR, Sharma G, Lee SS and Chakraborty C: MiRNA-regulated key components of cytokine signaling pathways and inflammation in rheumatoid arthritis. Med Res Rev 36: 425-439, 2016.
5. Habibi F, Ghadiri Soufi F, Ghiassi R, Khamaneh AM and Alipour MR: Alteration in inflammation-related miR-146a expression in NF-kB signaling pathway in diabetic rat hippocampus: Adv Pharm Bull 6: 99-103, 2016.
6. Stickel P, Prinz G, Pfeifer D, Hasselblatt P, Schmitt-Graeff A, Follo M, Thimm M, Thimme R, Finke J, Duyster J, Salzer U and Zeizer R: MiR-146a regulates the TRAF6/TNF-axis in donor T cells during GVHD. Blood 124: 2586-2595, 2014.
7. Taganov KD, Boldin MP and Baltimore D: MicroRNAs and immunity: Tiny players in a big field. Immunity 26: 133-137, 2007.
8. Perl A: Pathogenic mechanisms in systemic lupus erythematosus. Autoimmunity 43: 1-6, 2010.
9. Wang H, Peng W, Ouyang X, Li W and Dai Y: Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Transl Res 160: 198-206, 2012.
10. Ji JD, Chu ES and Lee WJ: Association of miR-146a polymorphisms with systemic lupus erythematosus: A meta-analysis. Lupus 23: 1023-1030, 2014.
11. Gao M, Wang X, Zhang X, Ha T, Ma H, Liu L, Kalbleisch JH, Gao X, Kao RL, Williams DL and Li C: MicroRNA regulation in human CD8+ T cell subsets -cytokine signaling pathway - in rat pulmonary arterial smooth muscle cells. J Immunol 195: 672-682, 2015.
12. Kaisto T and Aldra S: Toll-like receptor function and signaling. J Allergy Clin Immunol 117: 979-988, 2006.
13. Rodriguez-Pia A, Patel P, Maeker HT, Rossello-Urgell J, Baldwin N, Bennett L, Cantrell V, Baisch J, Punaro M, Gotte A, Baldwin N, Bennett L, Cantrell V, Baisch J, Punaro M, Gotte A, et al. IFN priming is necessary but not sufficient to turn on a migratory dendritic cell program in lupus monocytes. J Immunol 192: 5586-5598, 2014.
14. Wang P, Han X, Mo B, Huang G and Wang C; LPS enhances TLR4 expression and IFN-γ production via the TLR4/IRAK/MIKNF-κB signaling pathway in rat pulmonary arterial smooth muscle cells. Mol Med Rep 16: 3111-3116, 2017.
15. Nahid MA, Pauley KM, Satoh M and Chan EK: MiR-146a is critical for endotoxin-induced tolerance: Implication in innate immunity. J Biol Chem 284: 34590-34599, 2009.
16. Livak KJ and Schmittgen TD: Analysis of relative gene expression using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
17. Chen Y, Zeng Z, Shen X, Wu Z, Dong Y and Cheng JC: MicroRNA-146a-5p negatively regulates pro-inflammatory cytokine secretion and cell activation in lipopolysaccharide stimulated human hepatic stellate cells through inhibition of Toll-like receptor 4 signaling pathways. Int J Mol Sci 17: pii: E1076, 2016.
18. Muñoz LE, Janko C, Schulze C, Schorn C, Sarter K, Schett G and Herrmann M: Autoimmunity and chronic inflammation-two clearance-related steps in the etiopathogenesis of SLE. Autoimmun Rev 10: 38-42, 2011.
19. Dai Y, Huang YS, Tang M, Lv TY, Hu CX, Tan YH, Xu ZM and Yin YB: Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 16: 939-946, 2007.
20. Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, Huang X, Zhou H, de Vries N, Tak PP, et al. MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 60: 1065-1075, 2009.
21. Wigren M, Nilsson J and Kaplan MJ: Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: Common mechanisms and possible targets for intervention. J Intern Med 278: 494-506, 2015.
22. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT and Luster AD: Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 115: 407-417, 2005.
23. Husakova M: MicroRNAs in the key events of systemic lupus erythematosus pathogenesis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 160: 327-342, 2016.
24. Fang H, Wang PF, Zhou Y, Wang YC and Yang QW: Toll-like receptor 4 signaling in intracerebral hemorrhage-induced inflammation and injury. J Neuroinflammation 10: 27, 2013.
25. He X, Zheng Y, Liu S, Shi S, Liu Y, He Y, Zheng C and Zhou X: MiR-146a protects small intestine against ischemia/reperfusion injury by down-regulatingTLR4/TRAF6/NF-κB pathway. J Cell Physiol 223: 2476-2488, 2018.
26. Nahid MA, Satoh M and Chan EK: MicroRNA in TLR signaling and endotoxin tolerance. Cell Mol Immunol 8: 388-403, 2011.
27. Wang R, Seif AM, MCgwin G Jr, Martinez-Martinez K, Gonzalez EB, Dang N, Papalardo E, Liu J, Vilá LM, Revelle JD, et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: Data from LUMINA (LXXV), a multiethnic US cohort. Lupus 21: 830-835, 2012.
28. RIPLEY BJ, Goncalves B, Isenberg DA, Latchman DS and Rahman A: Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis 64: 849-853, 2005.
29. Sabry A, Shresha H, El-Husseini A, Mahmoud K, EldalshabKF, George SK, Abdel-Khaliek E, El-Shafey EM and Abo-Zenah H: Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE. Its correlation with disease activity, Cytokine 35: 148-153, 2006.
30. Arora V, Verma J, Marwah V, Kumar A, Anand D and Das N: Cytokine imbalance in systemic lupus erythematosus: A study on northern Indian subjects. Lupus 21: 596-603, 2012.
31. Gigante A, Gasperlini ML, Aletra A, Barbano B, Margiotta D, Cianci R, De Francesco I and Amoroso A: Cytokines expression in SLE nephritis. Eur Rev Med Pharmacol Sci 15: 15-24, 2011.
32. Robinson ES and Werth VP: The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine 73: 326-334, 2015.
33. Nahid MA, Satoh M and Chan EK: Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling. J Immunol 186: 1723-1734, 2011.
34. Da L, Chen X, Duan Z, Liu C, Zeng R, Chen Q and Li M: MiR-146a negatively regulatesdectin-1-induced inflammatory responses. Oncotarget 8: 37355-37366, 2017.
35. Mokhberjee N and El-Gabalawy HS: High degree of correlation between whole blood and PBMC expression levels of miR-155 and miR-146a in healthy controls and rheumatoid arthritis patients. J Immunol Methods 400-401: 106-110, 2013.
36. Sheppard HM, Verdon D, Brooks AE, Feisit V, Ho YY, Lorenz N, Fan V, Birch NP, Didsbury A and Dunbar PR: MicroRNA regulation in human CD8+ T cell subsets-cytokine exposure alone drives miR-146a expression. J Transl Med 12: 292, 2014.
37. Cho S, Lee HM, Yu IS, Choi YS, Huang HY, Hashemifar SS, Lin LL, Chen MC, Afanasiev ND, Khan AA, et al. Differential cell-intrinsic regulations of germinal center B and T cells by miR-146a and miR-146b in healthy controls and rheumatoid arthritis patients. J Immunol Methods 400-401: 106-110, 2013.
38. Robinson ES and Werth VP: The role of cytokines in the pathogenesis of systemic lupus erythematosus. Cytokine 73: 326-334, 2015.